Associations Between State Policies Facilitating Telehealth and Buprenorphine Episode Initiation and Duration Early in the COVID Pandemic : State Telehealth Policies and Buprenorphine

Overview

Journal J Gen Intern Med

Publisher Springer

Specialty General Medicine

Date 2024 Nov 14

PMID 39543071

Authors

Bradley D Stein

Brendan K Saloner

Flora Sheng

Mark Sorbero

Andrew W Dick

Adam J Gordon

Affiliations

Soon will be listed here.

Abstract

Importance: State policies facilitating telehealth implemented early in COVID may support buprenorphine treatment of opioid use disorder. However, little empirical information is available about those policies' effects.

Objective: Examine association between state policies that may facilitate telehealth use and buprenorphine treatment.

Design, Setting, Participants: Retrospective cohort study using 2019-2020 national pharmacy data on dispensed buprenorphine prescriptions.

Exposures: State policies implemented after March 3, 2020, public health emergency declaration requiring private insurers' telehealth reimbursement to be commensurate with in-person service reimbursement, authorizing Medicaid reimbursement for audio-only telehealth, allowing physicians to provide cross-state telehealth services, and allowing psychologists to provide cross-state telehealth services.

Main Outcomes And Measures: (a) Duration of treatment episodes started between March 1 and March 13 in both 2019 and 2020, and (b) daily numbers of new buprenorphine treatment episodes from March 13 through December 31 in each year.

Key Results: We found little change in the number of new buprenorphine treatment episodes started in 2020 compared to 2019 and an increase in treatment duration of 10.3 days (95%CI 8.3 to 12.2 days) for episodes started in March 2020 before the public health emergency declaration compared to the comparable 2019 period. States implementing a telehealth parity policy in 2020 had 7.3% (95%CI - 13.3% to - 0.4%) fewer new buprenorphine treatment episodes. States joining the psychologist interstate compact in 2020 after the public health emergency declaration had treatment episodes 7.97 days longer (95%CI 0.78 to 15.16) than other states. None of the other policies examined was associated with changes in new treatment episodes or treatment duration.

Conclusions And Relevance: Policies undertaken during the pandemic we examined were associated with few significant changes in buprenorphine treatment initiation and duration. Findings suggest realizing the benefits of telehealth and other policy changes for buprenorphine may require more extensive implementation and infrastructure support.

References

Alexander G, Stoller K, Haffajee R, Saloner B . An Epidemic in the Midst of a Pandemic: Opioid Use Disorder and COVID-19. Ann Intern Med. 2020; 173(1):57-58. PMC: 7138407. DOI: 10.7326/M20-1141. View

Czeisler M, Lane R, Petrosky E, Wiley J, Christensen A, Njai R . Mental Health, Substance Use, and Suicidal Ideation During the COVID-19 Pandemic - United States, June 24-30, 2020. MMWR Morb Mortal Wkly Rep. 2020; 69(32):1049-1057. PMC: 7440121. DOI: 10.15585/mmwr.mm6932a1. View

Taquet M, Luciano S, Geddes J, Harrison P . Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA. Lancet Psychiatry. 2020; 8(2):130-140. PMC: 7820108. DOI: 10.1016/S2215-0366(20)30462-4. View

Friedman J, Beletsky L, Schriger D . Overdose-Related Cardiac Arrests Observed by Emergency Medical Services During the US COVID-19 Epidemic. JAMA Psychiatry. 2020; 78(5):562-564. PMC: 7716252. DOI: 10.1001/jamapsychiatry.2020.4218. View

Friedman J, Mann N, Hansen H, Bourgois P, Braslow J, Bui A . Racial/Ethnic, Social, and Geographic Trends in Overdose-Associated Cardiac Arrests Observed by US Emergency Medical Services During the COVID-19 Pandemic. JAMA Psychiatry. 2021; 78(8):886-895. PMC: 8156174. DOI: 10.1001/jamapsychiatry.2021.0967. View

Khatri U, Pizzicato L, Viner K, Bobyock E, Sun M, Meisel Z . Racial/Ethnic Disparities in Unintentional Fatal and Nonfatal Emergency Medical Services-Attended Opioid Overdoses During the COVID-19 Pandemic in Philadelphia. JAMA Netw Open. 2021; 4(1):e2034878. PMC: 7821023. DOI: 10.1001/jamanetworkopen.2020.34878. View

Soares 3rd W, Melnick E, Nath B, DOnofrio G, Paek H, Skains R . Emergency Department Visits for Nonfatal Opioid Overdose During the COVID-19 Pandemic Across Six US Health Care Systems. Ann Emerg Med. 2021; 79(2):158-167. PMC: 8449788. DOI: 10.1016/j.annemergmed.2021.03.013. View

Goldman M, Druss B, Horvitz-Lennon M, Norquist G, Kroeger Ptakowski K, Brinkley A . Mental Health Policy in the Era of COVID-19. Psychiatr Serv. 2020; 71(11):1158-1162. DOI: 10.1176/appi.ps.202000219. View

Davis C, Carr D, Glenn M, Samuels E . Legal Authority for Emergency Medical Services to Increase Access to Buprenorphine Treatment for Opioid Use Disorder. Ann Emerg Med. 2021; 78(1):102-108. PMC: 8238848. DOI: 10.1016/j.annemergmed.2021.01.017. View

10.

Andraka-Christou B, Bouskill K, Haffajee R, Randall-Kosich O, Golan M, Totaram R . Common themes in early state policy responses to substance use disorder treatment during COVID-19. Am J Drug Alcohol Abuse. 2021; 47(4):486-496. PMC: 8564552. DOI: 10.1080/00952990.2021.1903023. View

11.

Pessar S, Boustead A, Ge Y, Smart R, Pacula R . Assessment of State and Federal Health Policies for Opioid Use Disorder Treatment During the COVID-19 Pandemic and Beyond. JAMA Health Forum. 2022; 2(11):e213833. PMC: 9138185. DOI: 10.1001/jamahealthforum.2021.3833. View

12.

Perumalswami P, Kilpatrick S, Frost M, Adams M, Kim H, Zhang L . The impact of COVID-19 on trends in alcohol use disorder treatment in Veterans Health Administration. Addiction. 2023; 118(6):1062-1071. DOI: 10.1111/add.16156. View

13.

Chalasani R, Shinabery J, Goetz C, Chang C, Yang Q, Suda K . Buprenorphine Dispensing in Pennsylvania During the COVID-19 Pandemic, January to October 2020. J Gen Intern Med. 2021; 36(12):3915-3917. PMC: 8354093. DOI: 10.1007/s11606-021-07083-y. View

14.

Currie J, Schnell M, Schwandt H, Zhang J . Prescribing of Opioid Analgesics and Buprenorphine for Opioid Use Disorder During the COVID-19 Pandemic. JAMA Netw Open. 2021; 4(4):e216147. PMC: 8050741. DOI: 10.1001/jamanetworkopen.2021.6147. View

15.

Cantor J, Dick A, Haffajee R, Pera M, Bravata D, Stein B . Use of buprenorphine for those with employer-sponsored insurance during the initial phase of the COVID-19 pandemic. J Subst Abuse Treat. 2021; 129:108384. PMC: 8546915. DOI: 10.1016/j.jsat.2021.108384. View

16.

Jones C, Guy Jr G, Board A . Comparing actual and forecasted numbers of unique patients dispensed select medications for opioid use disorder, opioid overdose reversal, and mental health, during the COVID-19 pandemic, United States, January 2019 to May 2020. Drug Alcohol Depend. 2021; 219:108486. PMC: 7787058. DOI: 10.1016/j.drugalcdep.2020.108486. View

17.

Huskamp H, Busch A, Uscher-Pines L, Barnett M, Riedel L, Mehrotra A . Treatment of Opioid Use Disorder Among Commercially Insured Patients in the Context of the COVID-19 Pandemic. JAMA. 2020; 324(23):2440-2442. PMC: 7739126. DOI: 10.1001/jama.2020.21512. View

18.

Cance J, Doyle E . Changes in Outpatient Buprenorphine Dispensing During the COVID-19 Pandemic. JAMA. 2020; 324(23):2442-2444. PMC: 7739121. DOI: 10.1001/jama.2020.22154. View

19.

Stein B, Landis R, Sheng F, Saloner B, Gordon A, Sorbero M . Buprenorphine Treatment Episodes During the First Year of COVID: a Retrospective Examination of Treatment Initiation and Retention. J Gen Intern Med. 2022; 38(3):733-737. PMC: 9734477. DOI: 10.1007/s11606-022-07891-w. View

20.

Langabeer 2nd J, Yatsco A, Champagne-Langabeer T . Telehealth sustains patient engagement in OUD treatment during COVID-19. J Subst Abuse Treat. 2020; 122:108215. PMC: 7685137. DOI: 10.1016/j.jsat.2020.108215. View